Milestone shares jump 10.40% intraday as CARDAMYST is added to Express Scripts national formulary, expanding access for commercial insured patients.

Milestone surged 10.40% intraday, as the company announced that Express Scripts, the largest pharmacy benefits manager in the U.S., added CARDAMY tetrapamil nasal spray to its commercial national formulary effective March 27. This inclusion makes the drug widely accessible to commercial insurance populations nationwide. CARDAMY is the first and only FDA-approved nasal spray for self-administration in adults with paroxysmal supraventricular tachycardia (PSVT), and this agreement marks the company’s first formulary contract with a major payer, significantly enhancing drug accessibility.